Selecta Biosciences, Inc. Announces Successful Pre-Clinical Study Of SEL-201 As An Antigen-Specific Immune Tolerance Treatment For Patients Receiving Factor VIII Therapy

Published: Dec 09, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

WATERTOWN, Mass.--(BUSINESS WIRE)--Selecta Biosciences, Inc., a clinical stage biotechnology company developing a novel class of targeted antigen-specific immune tolerance treatments, today announced that data from a pre-clinical proof of concept study in Factor VIII-deficient mice were presented in a poster presentation at the 2013 American Society for Hematology (ASH) International Conference in New Orleans. SEL-201 demonstrated the ability to induce immune tolerance in a model of hemophilia A, showing that SEL-201 has the potential to serve as an adjunct therapy to avoid harmful neutralizing antibody response to Factor VIII treatment severely affecting hemophilia A patients.

Help employers find you! Check out all the jobs and post your resume.

Back to news